このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Integrum マネジメント

マネジメント基準チェック /24

現在、CEO に関する十分な情報がありません。

主要情報

Rickard Branemark

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	2.2yrs
CEOの所有権	n/a
経営陣の平均在職期間	1.5yrs
取締役会の平均在任期間	4.5yrs

経営陣の近況

Recent updates

CEO（最高経営責任者

Rickard Branemark (64 yo)

2.2yrs

在職期間

SEK 3,399,928

報酬

Dr. Rickard Brånemark, MD, PhD is the Founder and Owner of Integrum AB and serves as Chief Executive Officer since May 19, 2022. Previously served as Chief Executive Officer from 1998 to 2015. He serves as...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Rickard Branemark	Owner, CEO	2.2yrs	SEK 3.40m	データなし
Jorgen Svanstrom	Interim Chief Finance Officer	1.2yrs	データなし	データなし
Mats Dotevall	COO & Site Manager	1.5yrs	データなし	データなし
Karin Ganlöv	Chief Medical Officer	2.2yrs	データなし	データなし
Jeffrey Zanni	President of U.S. & Head of American Operations	less than a year	データなし	データなし
Anna-Tove Branemark	Chief Executive Officer of Integrum Inc.	no data	データなし	データなし

1.5yrs

平均在職期間

60yo

平均年齢

経験豊富な経営陣: INTEG Bの経営陣は経験豊富とはみなされません ( 1.4年の平均在職年数)。これは新しいチームを示唆しています。

取締役

名称	ポジション	在職期間	報酬	所有権
Rickard Branemark	Owner, CEO	no data	SEK 3.40m	データなし
Scott Flora	Director	less than a year	データなし	データなし
Bengt Sjoholm	Chairman	4.7yrs	SEK 100.00k	データなし
Karin Wingstrand	Director	no data	SEK 100.00k	0.20% SEK 1.9m
Andrew Christensen	Director	no data	SEK 100.00k	データなし
Patric Lindgren	Independent Director	4.5yrs	SEK 376.29k	データなし
Cecilia Wikstrom	Independent Director	4.5yrs	SEK 100.00k	データなし

4.5yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: INTEG Bの取締役会は経験豊富であると考えられます ( 4.4年の平均在任期間)。

Integrum マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Less than half of directors are independent

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum AB (Publ) Announces Management Changes

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Recent updates

Consensus EPS estimates fall by 37%, revenue upgraded

Full year 2024 earnings released: EPS: kr0.23 (vs kr0.88 loss in FY 2023)

Price target increased by 7.3% to kr77.25

Integrum AB (publ) to Report Q3, 2025 Results on Mar 03, 2025

Integrum Announces It Has Been Granted A Registered Trademark for OPRA® Implant System in the Eu

We Think Integrum (STO:INTEG B) Can Easily Afford To Drive Business Growth

Less than half of directors are independent

Third quarter 2024 earnings released: EPS: kr0.05 (vs kr0.74 loss in 3Q 2023)

Integrum AB (publ) to Report Q3, 2024 Results on Feb 29, 2024

Second quarter 2024 earnings released: EPS: kr0.21 (vs kr0.21 in 2Q 2023)

Consensus revenue estimates increase by 15%

New major risk - Revenue and earnings growth

Integrum AB (publ) Plans to Submit a PMA Application to the FDA for the Use of OPRA in Transhumeral Implantations Based on Existing Clinical Data

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (Publ) Provides Earnings Guidance for the Second Quarter of 2023

Integrum AB (publ) to Report Q2, 2024 Results on Dec 04, 2023

Integrum (Publ) Announces US Department of Defense Decided to Fully Fund a Clinical Study of OPRA(TM) Implant System on Up to 30 Patients with Transtibial (Below-Knee) Amputations

Integrum's Opra™? Implant System Gets Fda Approval for Clinical Study on Below-Knee Amutationations

New minor risk - Profitability

Integrum (Publ) Announces Long-Term Follow-Up Patient Who Received A Human-Machine Bionic Hand Prosthesis, Utilizing

Integrum Announces Long-Term Integrated Bionic Hand Enriched with Motor and Sensory AI

Integrum Receives Unitary Patent for Neuromotus in the EU

Integrum AB (Publ) Appoints Scott Flora as Full Board Member

Integrum Initiates A Strategic Review Process to Accelerate Growth

Integrum AB Receives Reimbursement Code for Axor II

Integrum (Publ) Announces First Case Study of A Person with Above-Elbow Implantation Obtains Unprecedented Control of Every Finger in A Bionic Hand

Integrum AB (Publ) Announces Management Changes

Consensus revenue estimates decrease by 12%

Price target decreased by 31% to kr72.00

New minor risk - Share price stability

Full year 2023 earnings: Revenues miss analyst expectations

Integrum Announces the Appointment of Scott Flora as Adjunct Board Member

Consensus revenue estimates decrease by 40%

Third quarter 2023 earnings released

Integrum (publ) Appoints Annika Fahlén as Director of Quality Assurance and Regulatory Affairs, Effective 1 April 2023

Integrum AB (Publ) Announces Dennis Baecklund to Leave the Company as CFO

Consensus forecasts updated

Second quarter 2023 earnings released

Integrum Provides an Update on the Clinical Development Programs of e-OPRATM Implant System and Neuromotus

Less than half of directors are independent

Investor sentiment improved over the past week

Integrum AB (publ) Is Granted Patent Approval for Its OPRA Implant System from the Us Patent and Trade Organization

Investor sentiment deteriorated over the past week

Investor sentiment deteriorated over the past week

Does Integrum (STO:INTEG B) Deserve A Spot On Your Watchlist?

First quarter 2023 earnings released

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Full year 2022 earnings released

Integrum AB (publ) to Report Q2, 2023 Results on Dec 05, 2022

Integrum AB (publ) Announces Board Changes

Integrum AB (Publ) Appoints Karin Ganlöv as Chief Medical Officer

Price target decreased to kr100.00

Less than half of directors are independent

Investor sentiment improved over the past week

Third quarter 2022 earnings: Revenues exceed analyst expectations

Integrum AB (publ) to Report Fiscal Year 2022 Results on Jun 10, 2022

Investor sentiment deteriorated over the past week

Owner & Chairman exercised options to buy kr1.4m worth of stock.

Investor sentiment improved over the past week

Integrum's (STO:INTEG B) Earnings Aren't As Good As They Appear

Second quarter 2022 earnings: EPS in line with expectations, revenues disappoint

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

Forecast to breakeven in 2023

First quarter 2022 earnings released

Full year 2021 earnings released: kr0.038 loss per share (vs kr1.04 loss in FY 2020)

マネジメント基準チェック /24